Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BYON5667 + SYD985
- Development stage
- Unknown
- Lead developer
- Byondis
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Ophthalmic, Intravenous
01
Overview
BYON5667 + SYD985 is a combination therapeutic regimen developed by Byondis B.V. to mitigate the ocular toxicities associated with the antibody-drug conjugate (ADC) SYD985 (trastuzumab duocarmazine). SYD985 is a HER2-targeting ADC that utilizes a duocarmycin-based DNA-alkylating payload (seco-DUBA) linked via a cleavable valine-citrulline linker. While effective in treating HER2-expressing cancers such as breast and endometrial cancer, SYD985 frequently causes ocular adverse events, including keratitis and conjunctivitis, likely due to off-target uptake of the payload in the eye. BYON5667 is a prophylactic ophthalmic formulation of sodium thiosulfate designed to neutralize the cytotoxic payload within the ocular environment, thereby reducing the severity and incidence of these side effects. This combination is currently being evaluated in Phase 1/2 clinical trials.
- Other names
- sodium thiosulfate + trastuzumab duocarmazinesodium thiosulfate eye drops + SYD985
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BYON5667 + SYD985.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BYON5667 + SYD985.